| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
the present review, the reader will be led to the most relevant
observations that prompted oncologists and haematologist to consider
FDG-PET/CT as a new paradigm for FL management in clinical practice.
The role of functional imaging in lymphoma staging, restaging,
prognostication, and metabolic tumour volume computing will be reviewed
in detail. Moreover, a special focus will be addressed to technical and
practical aspects of PET scan reporting, which have been set during the
last decade to ensure the reproducibility of the therapeutic results.
Finally, the predictive role of PET/CT on long-term treatment outcome
will be compared with another well-known prognosticator as minimal
residual disease (MRD) detection by Immunoglobulin gene rearrangement
FDG-PET PET for FL Staging
DG-PET for FL Prognostication at Baseline
|Figure 1. 5-Y PFS and OS according to baseline Total Metabolic Tumour Volume (TMTV). From Meignan et al.|
FDG-PET for Treatment Response Evaluation in FL
|Figure 2. OS according to PET scan score. From Trotman et al.|
FDG-PET for Radioimmunotherapy (RIT)